Page last updated: 2024-09-04

naproxen and Acute Relapsing Multiple Sclerosis

naproxen has been researched along with Acute Relapsing Multiple Sclerosis in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hendin, B; Huang, D; Naismith, RT; Rosenblatt, S; Werneburg, B; Wray, S; Zambrano, J	1
Filipi, M; Healey, K; Leuschen, MP	1

Trials

2 trial(s) available for naproxen and Acute Relapsing Multiple Sclerosis

Article	Year
Subcutaneous peginterferon β-1a injection-site reaction experience and mitigation: Delphi analysis of the ALLOW study. Neurodegenerative disease management, 2017, Volume: 7, Issue:1 Topics: Adjuvants, Immunologic; Adult; Aged; Delphi Technique; Drug Eruptions; Humans; Interferon-beta; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Naproxen; Polyethylene Glycols; Treatment Outcome	2017
A randomized open label study of pain medications (naproxen, acetaminophen and ibuprofen) for controlling side effects during initiation of IFN beta-1a therapy and during its ongoing use for relapsing-remitting multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England), 2004, Volume: 10, Issue:6 Topics: Acetaminophen; Adjuvants, Immunologic; Adult; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Drug Therapy, Combination; Fatigue; Female; Humans; Ibuprofen; Interferon beta-1a; Interferon-beta; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Naproxen; Pain; Prospective Studies	2004

Article

Year

Subcutaneous peginterferon β-1a injection-site reaction experience and mitigation: Delphi analysis of the ALLOW study.

Neurodegenerative disease management, 2017, Volume: 7, Issue:1

Topics: Adjuvants, Immunologic; Adult; Aged; Delphi Technique; Drug Eruptions; Humans; Interferon-beta; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Naproxen; Polyethylene Glycols; Treatment Outcome

2017

A randomized open label study of pain medications (naproxen, acetaminophen and ibuprofen) for controlling side effects during initiation of IFN beta-1a therapy and during its ongoing use for relapsing-remitting multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England), 2004, Volume: 10, Issue:6

Topics: Acetaminophen; Adjuvants, Immunologic; Adult; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Drug Therapy, Combination; Fatigue; Female; Humans; Ibuprofen; Interferon beta-1a; Interferon-beta; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Naproxen; Pain; Prospective Studies

2004